Month: January 2021
Excerpt from the Press Release: DURHAM, NC, USA I January 8, 2021 I Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead…
Read More
Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Jan. 11, 2021 /PRNewswire/ — NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) (“Relief”), and the Quantum Leap Healthcare Collaborative (“Quantum Leap”) of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100TM: aviptadil) in the I-SPY COVID-19 Clinical…
Read More
Excerpt from the Study Abstract: Mebomine – Clinical Insights From Online Patient Communities Objectives Online health forums provide rich and untapped real-time data on population health. Through novel data extraction and natural language processing (NLP) techniques, we characterise the evolution of mental and physical health concerns relating to the COVID-19 pandemic among online health forum…
Read More
Excerpt from the Article To encourage collaboration among its chapters, the Northeast Regional Board of the Latino Medical Student Association (LMSA) recently tasked chapters in various cities to work together to develop and implement a community service project for their local Latino community. “Our group included Jefferson, Penn, Drexel, PCOM and Temple,” says second-year Temple…
Read More
Excerpt from the Article: Two more life-saving drugs have been found that can cut deaths by a quarter in patients who are sickest with Covid. The anti-inflammatory medications, given via a drip, save an extra life for every 12 treated, say researchers who have carried out a trial in NHS intensive care units. Supplies are…
Read More
Excerpt from the Article: AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has announced Wednesday that the active AMP-511 Expanded Access Program (EAP) has dosed its first coronavirus (COVID-19) “Long Hauler” patient with the drug Ampligen (rintatolimod). The company said the initial dosing marks a significant milestone in its efforts to develop an effective therapeutic for people suffering…
Read More
Excerpt from the Article: In 1995, Katalin Karikó was at her lowest ebb. A biochemist at the University of Pennsylvania (UPenn), Karikó had dedicated much of the previous two decades to finding a way to turn one of the most fundamental building blocks of life, mRNA, into a whole new category of therapeutics. More often…
Read More
Excerpt from the Article: COVID-19 is known to cause neurological complications in patients who test positive for the virus, but new research from the National Institutes of Health (NIH) has revealed that SARS-CoV-2 does not always find its way into the brains of infected patients. Based on findings from high-powered MRI scans, researches from the…
Read More
Excerpt from the Press Release: Researchers at Children’s Hospital of Philadelphia (CHOP) have formed a new consortium that will study the effects of the COVID-19 pandemic on preterm birth and prenatal care, funded by $300,000 in grants from the Independence Blue Cross Foundation, Highmark Blue Cross Blue Shield Delaware’s donor-advised fund, and BluePrints for the…
Read More
Excerpt from the Article: A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat Covid-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational…
Read More